Addressing Disparities in the Care of Patients with Non-Valvular Atrial Fibrillation
Premiere Date: Tuesday, April 19, 2022This activity offers CE credit for:
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, April 19, 2023
Note: Credit Is No Longer Available
 | Geoffrey Barnes, MD, MSc (Moderator) Assistant Professor, Cardiovascular Medicine and Vascular Medicine Department of Internal Medicine, Division of Cardiovascular Medicine University of Michigan Health System Ann Arbor, MI |
 | Utibe R. Essien, MD, MPH (he/him/his) Assistant Professor of Medicine Assistant Vice Chair, Equity Diversity and Inclusion Department of Medicine David Geffen School of Medicine at University of California, Los Angeles Los Angeles, CA |
 | Lauren A. Eberly, MD, MPH (she/her/hers) Fellow, Division of Cardiovascular Medicine Perelman School of Medicine, University of Pennsylvania Leonard Davis Institute of Behavioral Economics Philadelphia, PA |
Although direct oral anticoagulant (DOAC) therapy is a guideline-recommended strategy in patients with non-valvular atrial fibrillation (AF), it is frequently underutilized. Reasons for suboptimal DOAC therapy and associated disparities in quality of care may include failure by clinicians to recognize and address social determinants of health (SDOH), reluctance to include patients in shared decision-making (SDM), assumptions that patients will not be able to afford or will not be adherent to therapies, and possible implicit bias by health care professionals (HCPs) and institutions. Recognizing and addressing SDOH provides an important opportunity for clinicians to improve care and outcomes for patients with AF.
In this OnDemand CMEO webcast, you’ll hear unique perspectives from three experts in cardiology about anticoagulation strategies to prevent stroke in AF, with an emphasis on revealing and addressing disparities in care among patients from diverse racial/ethnic backgrounds, women, older patients, and patients with other comorbid conditions.
At the end of this CE activity, participants should be able to:
- Recognize SDOH and their connection to disparities in care for patients with NVAF in diverse and underserved populations.
- Assess SDOH and possible implicit bias to endure equitable screening and risk stratification for all patients with suspected NVAF.
- Tailor individual treatment plans for patients with NVAF while considering SDOH to provide optimal guideline-directed care.
Supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.
Physicians, PAs, nurse practitioners, nurses, and pharmacists and other health care providers specializing in cardiology, primary care, and care of patients with NVAF
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning Formats
Enduring Material
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Barnes reports the following financial relationships:
Consultant: Acelis Connected health; AMAG Pharmaceuticals; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; and Pfizer Inc.
Grants: Agency for Healthcare Research and Quality (AHRQ); Blue Cross Blue Shield of Michigan; Boston Scientific; and National Heart, Lung, and Blood Institute (NHLB)
Other Financial or Material Support: Board of Directors - Anticoagulation Forum, National Certification Board of Anticoagulation Providers
Dr. Essien reports the following financial relationships:
Grants: Department of Veterans Affairs Health Services Research and Development Division
Dr. Eberly reports no financial relationships.
The following Peer Reviewer and CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
WCV-047-041922-08
